A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
This study is testing an experimental medication called MRTX1719 for patients with advanced solid tumors. Researchers want to see how safe the drug is and how well it fights cancer cells that have a specific genetic change called an MTAP gene deletion.
You may be able to join if you are 18 or older, in good general health, and have an advanced solid tumor with the MTAP gene deletion that has spread or cannot be removed by surgery. Certain prior treatments, untreated brain metastases, or severe health issues will mean you cannot participate.
Participants will receive the study drug and have their health closely monitored by the medical team. Because this is an early-stage study, you will also need to provide safe tissue samples from your tumor before and during the treatment.
This study is currently recruiting patients at multiple locations in the United States, including cities in Arizona, Colorado, and Florida. Your care team can help you find the closest participating medical center.
- 1Testing a new drug called MRTX1719 for specific advanced cancers
- 2Requires a genetic test showing an MTAP gene deletion
- 3Involves regular safety check-ups and tissue sample collections
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.